riliprubart

Phase 3Small molecule

riliprubart is one of 15 small molecule programs targeting Chronic Inflammatory Demyelinating Polyradiculoneuropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Inflammatory Demyelinating PolyradiculoneuropathyActive, not recruiting

Polyneuropathy, Inflammatory Demyelinating, ChronicEnrolling by invitation

Chronic Inflammatory Demyelinating PolyneuropathyRecruiting

Chronic Inflammatory Demyelinating PolyradiculoneuropathyPhase 3

Active, not recruiting

Polyneuropathy, Inflammatory Demyelinating, ChronicPhase 3

Enrolling by invitation

Chronic Inflammatory Demyelinating PolyneuropathyPhase 3

Recruiting

Competition

Competitive Landscape

10 competitors in Chronic Inflammatory Demyelinating Polyneuropathy

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

2 2

Empasiprubart

Argenx

Phase 3

2 3

Vyvgart

Argenx

Phase 2

3 4

Cytoxan

BBaxter Healthcare Corporation

Phase 2

2 5

Fludara

Sanofi

Phase 1

1 6

riliprubart

Sanofi

Phase 3

1 7

Claseprubart

DDianthus Therapeutics

Phase 3

1 8

Ripertamab

ZZhongming Qiu

Phase 3

1 9

Panzyga

Octapharma

Phase 3

1 10

KITE-363

Gilead

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Active, not recruiting

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

NCT06290128

Q1 2029

Phase 3Recruiting

Chronic Inflammatory Demyelinating Polyneuropathy

NCT06290141

Clinical

Trials by Indication[1]

Polyneuropathy, Inflammatory Demyelinating, Chronic1 trial

Long-term Extension Study to Evaluate the Safety and Efficacy of Riliprubart (SAR445088) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Enrolling by invitation· Sanofi logo

Sanofi·Phase 3·NCT06859099·300 enrolled

Chronic Inflammatory Demyelinating Polyradiculoneuropathy1 trial

A Phase 3, Double-blind, Placebo-controlled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy

Active, not recruiting· Sanofi logo

Sanofi·Phase 3·NCT06290128·109 enrolled

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy

Recruiting· Sanofi logo

Sanofi·Phase 3·NCT06290141·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for riliprubart. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — riliprubart compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for riliprubart. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sanofi

riliprubart

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2029

Trials by Indication[1]

Polyneuropathy, Inflammatory Demyelinating, Chronic1 trial

Chronic Inflammatory Demyelinating Polyradiculoneuropathy1 trial

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

References

Drug Info

Quick Facts

Related News